|
|
Profile
|
Delegates :
Chizuko Koseki |
|
Incorporated :
March 22 , 2007 |
Paid in Capital :
290 Million yen |
Employees :
9 人 |
Address :
The University of Tokyo, Komaba Open Laboratory 403 4-6-1 Komaba, Meguro-ku, TOKYO
〒153-8505
|
TEL/FAX :
+81-3-6407-1672 / +81-3-6407-1673 |
URL：
http://tagcyx.com/en/ |
Attachment :
|
Mission/Background :
TAGCyx was founded in 2007, as a spin-out company of Riken Research Institute. |
|
Technology & Business
|
TAGCyx focuses on creating novel nucleic acid based drugs for pharmaceutical applications. TAGCyx has established a revolutionary nucleic acid-based drug discovery platform, “Xenoligo(TM) system”. It enables screening of drug candidates from large oligonucleotide libraries containing hydrophobic non-natural bases, in addition to optimize its stability using our proprietary technology. Xenoligo(TM) molecules show high affinity against their target, which provides significant advantages compared to small molecule and protein therapeutics.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Xenoligo(TM) technology platform
|
Discovery
|
Xenoligo(TM) can generate high affinity oligonucleotide therapeutic products as new modality.
|
Identify pharmaceutical partners
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
We have fully executed a research and development alliance with an European biopharma company in 2017.
|
|
Alliance strategy
|
Executing research and development collaboration with both Japanese and global pharmaceutical companies.
|
|
|